Week of Dec. 20, 2010: Company and People Notes: Pfizer Recalls One Lipitor Lot; Sanofi Aventis Names Head of R&D; and More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Dec. 20, 2010: Company and People Notes: Pfizer Recalls One Lipitor Lot; Sanofi Aventis Names Head of R&D; and More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company Notes

Contract manufacturing organization Aesica Pharmaceuticals will purchase three manufacturing sites in Germany and Italy from the biopharmaceutical company UCB. Aesica will acquire the German sites in Monheim and Zwickau, as well as UCB’s Pianezza, Italy site. The companies also formed a long-term supply agreement.

Biogen Idec (Weston, MA) acquired a subsidiary of Neurimmune Holding (Zurich), which includes the worldwide rights to three preclinical immunotherapy programs focused on human antibodies. Biogen Idec will make an initial payment of $32.5 million and up to $395 million in contingent payments. The programs address three central nervous system targets, alpha-synuclein, tau, and TDP-43, which are believed to be relevant for the treatment of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). This acquisition builds on a 2007 agreement between the two companies to explore human antibodies.

bluebird bio (formerly Genetix Pharmaceuticals, Cambridge, MA), a company focused on gene therapies for severe genetic disorders, and Généthon, a not-for-profit research center focused on gene-therapy treatments for rare diseases, will collaborate on process development and scale-up efforts for the manufacturing of lentiviral vectors. Specific terms of the agreement were not disclosed.

Bristol-Myers Squibb (New York) formed a drug-development pact with biotechnology company Oncolys BioPharma (Tokyo) for festinavir, a once-a-day nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV. Oncolys may receive up to $286 million in milestone payments and is also eligible to receive tiered royalties on product sales.

DSM Pharmaceutical Products (Parsippany, NJ), the custom manufacturing organization of Royal DSM (Heerlen, The Netherlands), formed a license agreement with the biotechnology company c-LEcta GmbH (Leipzig, Germany), an industrial biotechnology, for proprietary screening technology.
The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.

Eli Lilly and Company (Indianapolis) completed the acquisition of Avid Radiopharmaceuticals (Philadelphia), a company developing molecular imaging compounds for the detection of chronic human diseases. Lilly acquired all outstanding shares of Avid for an upfront payment of $300 million, subject to adjustment based on existing cash on hand at closing. Avid stockholders will also be eligible for up to $500 million in additional payments contingent on regulatory and commercial milestones for florbetapir, a molecular imaging agent under investigation for detecting the presence of amyloid plaque in the brain. The transaction, first announced on November 8, 2010, met all closing conditions. The impact of the acquisition will be reflected in Lilly's fourth quarter 2010 financial statements, but is not expected to be material.

Emisphere Technologies (Cedar Knolls, NJ), a biopharmaceutical company, formed a drug-delivery pact with the healthcare company Novo Nordisk (Bagsværd, Denmark). The companies will work to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen Technology. The agreement includes $57.5 million in potential milestone payments to Emisphere, of which $5 million will be payable upon signing, as well as royalties on sales. This is the second license agreement between the two companies.

Gilead Sciences (Foster City, CA) agreed to acquire the biotechnology company Arresto Biosciences (Palo Alto, CA) for $225 million and potential future sales-based milestone payments. Gilead expects the deal to close in the first quarter of 2011, pending regulatory approval.

GlaxoSmithKline (London) and Impax Pharmaceuticals, the brand products division of the specialty pharmaceutical company Impax Laboratories (Hayward, CA), will collaborate to develop and commercialize IPX066, Impax’s extended release carbidopa-levodopa product designed to treat Parkinson’s Disease currently in Phase III clinical trials. GSK will pay Impax an $11.5-million upfront payment, milestone payments of up to $175 million, and royalties on product sales for an exclusive license to commercialize IPX066 throughout the world except in the US and Taiwan.

Novartis (Basel) agreed to a merger agreement under which Novartis will acquire the remaining part of the eye-care company Alcon (Hünenberg,
Switzerland) for $12.9 billion, or $168 per share. The new Alcon division of Novartis will be led by Kevin Buehler, current president and CEO of Alcon.

Novavax (Rockville, MD) received clearance from FDA for its Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection; the program is no longer on clinical hold. In November, the company reported that it had received a question from FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

Pfizer (New York) recalled one lot—approximately 19,000 bottles—of Lipitor (atorvastatin calcium) 40 mg tablets distributed in the US. The product was recalled because of complaints of an “uncharacteristic odor” attributed to contamination by 2,4,6 tribromoanisole (TBA), which can stem from the use of the chemical 2,4,6-tribromonophenol (TBP) as a preservative on wooden pallets that are used to transport and store products. Pfizer said it prohibits the use of TBP-treated wood in the shipment of its medicines.

Phylogica (Perth, Australia), a drug-discovery company, signed a drug-discovery agreement with Pfizer (New York) for peptide-based vaccines. Phylogica will use its proprietary Phylomer drug-discovery platform to identify Phylomer peptides suitable for further evaluation. Phylogica will receive an upfront payment of $500,000 and will be eligible for milestone payments of up to $134 million, as well as royalties on worldwide sales. Phylogica grants Pfizer licensing and commercialization rights.

Royal DSM (Heerlen, The Netherlands) will form a 50/50 global joint venture (JV) for its business group DSM Anti-Infectives with the Chinese chemical company Sinochem Group (Beijing). As part of the JV agreement, Sinochem will take a 50% equity interest in DSM Anti-Infectives for €210 million ($275.7 million) on a cash and debt-free basis. The JV will be headquartered in Hong Kong, and all 2000 DSM Anti-Infectives employees will be part of the new entity. The parties anticipate closing to take place in the second quarter of 2011.

Sanofi-aventis (Paris) and Ascendis Pharma (Palo Alto, CA) formed a global licensing and patent-transfer agreement on Ascendis’ proprietary drug-delivery technology TransCon Linker and Hydrogel carrier. The technologies are designed to allow controlled release of a drug, and TransCon Linker has shown encouraging results in preclinical studies in delivering insulin, according to a company press release.

Sanofi-aventis (Paris) signed a drug-development pact with Avila Therapeutics (Waltham, MA) to discover targeted covalent drugs for the treatment of cancers. sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds resulting from the discovery collaboration. Avila will receive up to $40 million in upfront and research support payments, and is eligible to receive uup to $154 million in milestone payments if the product is approved in the US, Europe, and Japan. Avila may also receive staged royalties on product sales.

Sanofi-aventis (Paris) signed a research and development deal with Merck KGaA (Darmstadt, Germany) to investigate experimental combinations of agents that could block specific pathways in cancer cells. The combinations involve Merck Serono’s MEK inhibitor MSC1936369B (also known as AS703026), sanofi-aventis’s PI3K/mTOR inhibitor SAR245409 (also known as XL765) and class I PI3K inhibitor SAR245408 (also known as XL147), respectively.

People Notes

Cephalon’s (Frazer, PA) founder, chairman, and CEO Frank Baldino, Jr. passed away last Thursday evening. The company mourns his passing and extends its sympathies to the entire Baldino family.

Johnson & Johnson (New Brunswick, NJ) appointed Alex Gorsky, currently worldwide chairman of medical devices and diagnostics, and Sheri McCoy, currently worldwide chairman of pharmaceuticals, to the positions of vice-chairmen of the executive committee, effective Jan. 3, 2011. Gorsky and McCoy will join William C. Weldon, chairman of the board and CEO, in an expanded Office of the Chairman.

Pier Pharmaceuticals (Louisville, CO), a clinical-stage biopharmaceutical company focused on the treatment of sleep-related breathing disorders, appointed Peter W. Letendre as its CEO, president, and member of the board of directors. The company was formerly known as Steady Sleep Rx.

Sanofi-aventis (Paris) appointed Elias Zerhouni president of global research and development, covering medicines and vaccines, effective January 1, 2011. Zerhouni will report directly to Christopher A. Viehbacher, the company's CEO.

The Procter & Gamble Company (Cincinnati) appointed Susan Desmond-Hellmann, chancellor of the University of California, San Francisco, to its board of directors.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here